Award Number: W81XWH-12-1-0467

TITLE: Targeting Nuclear EGFR: Strategies for Improving Cetuximab Therapy in Lung Cancer

PRINCIPAL INVESTIGATOR: Deric L Wheeler

CONTRACTING ORGANIZATION: University of Wisconsin
Madison, WI 53715

REPORT DATE: September 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Targeting Nuclear EGFR: Strategies for Improving Cetuximab Therapy in Lung Cancer

Deric L Wheeler, Toni M. Brand, Mari Iida

E-Mail: dlwheeler@wisc.edu

University of Wisconsin
21 N Park St Suite 6401
Madison, WI 53715-1218

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

NSCLC is a deadly disease that is driven by a multitude of factors. One of these factors is the epidermal growth factor receptor (EGFR). One of the most prominent molecular targeting agents to the EGFR is the antibody cetuximab. However, most patients develop resistance to this antibody. We have found in models of cetuximab resistance that the EGFR changes its location, to the nucleus, where it is not accessible to the large antibody. Our work over the last several years has discovered how to target the nEGFR, by blocking its translocation to the nucleus through Src Family Kinase blockade. In this first year we have determined 1) that nEGFR can serve as a prognostic factor in early stage NSCLC patients, 2) we have determined that we can target nEGFR in vivo and redistribute to the membrane in vivo, a critical first step for re-sensitizing to cetuximab and 3) developed a new avenue by developing a novel EGFR mutant that lacks its transcriptional potential. This will allow us to directly test the role of nEGFR in biology and cetuximab resistance.

15. SUBJECT TERMS

cetuximab resistance, nuclear EGFR, dasatinib, non-small cell lung cancer
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>Body</td>
<td>3</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>6</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>6</td>
</tr>
<tr>
<td>Conclusion</td>
<td>6</td>
</tr>
<tr>
<td>References</td>
<td>7</td>
</tr>
<tr>
<td>Appendices</td>
<td>None</td>
</tr>
</tbody>
</table>
INTRODUCTION:

The goals of this proposal are to 1) determine if targeting the nuclear EGFR (nEGFR) signaling pathway can increase the efficacy of anti-EGFR antibody based therapies in non-small cell lung cancer (NSCLC) and 2) determine if nEGFR can serve as a prognostic factor in NSCLC.

The EGFR is a ubiquitously expressed receptor tyrosine kinase (RTK) involved in the etiology of NSCLC. With this, intense efforts have been undertaken to stop EGFR function. These efforts have been highly fruitful as four drugs, including two small tyrosine kinase inhibitors (TKIs, gefitinib and erlotinib) and two antibodies (cetuximab and panitumumab), have moved to the clinic to target EGFR in NSCLC patients. In 2004, the identification of specific genetic mutations within the EGFR kinase domain of adenocarcinomas of the lung that predict response to EGFR-TKIs represented a landmark development in the EGFR field. Unfortunately, no such mutations that predict response to cetuximab have yet been identified. Clinical trials (FLEX trial\(^1\)) investigating cetuximab in NSCLC showed clinical benefit. However, not all patients respond to cetuximab therapy and most acquire resistance to cetuximab.

It is well established that the EGFR can rely on two distinct compartments of signaling: 1) Classical membrane bound signaling (classical EGFR pathway)\(^2\) and 2) nuclear signaling (nEGFR pathway)\(^3\). In the nEGFR pathway, recent data suggests that the EGFR is phosphorylated by Src family kinases (SFKs)\(^4,5\) and AKT\(^6\), which are necessary, early, events for trafficking EGFR from the membrane to the nucleus. In the nucleus EGFR is able to promote the transcription of genes essential for cell proliferation and cell cycle regulation\(^6-12\).

To explore molecular mechanisms of resistance to cetuximab in NSCLC our lab developed a series of cetuximab-resistant models using NSCLC cancer lines\(^13\). During investigations into potential molecular mechanisms of resistance we found that NSCLC tumor cells that acquired resistance to cetuximab had increased SFK activity \(^14\) and increased nEGFR\(^5\). Further investigation revealed that SFKs regulate EGFR translocation to the nucleus\(^5\) and the nuclear activity of EGFR contributes to resistance to cetuximab therapy\(^5\). However, this preliminary work has led to several questions that form the focus of this application: 1) Can blocking SFK and AKT activity decrease nuclear translocation of the EGFR in vivo, 2) will this lead to increased expression of EGFR on the cell membrane, 3) will this increase sensitivity to cetuximab therapy and 4) what is the prevalence of nEGFR in NSCLC patient biopsies and can it serve as a prognostic factor? In this proposal we hypothesize that nEGFR contributes to NSCLC resistance to cetuximab and that targeting nEGFR, by abrogating its translocation to the nucleus via SFK or AKT inhibition, followed by targeting membrane bound EGFR with cetuximab will increase therapeutic response of NSCLC tumors to cetuximab. To test this hypothesis we propose the following specific aims:

Specific Aim 1: To determine if SFK or AKT inhibition can 1) block EGFR translocation to the nucleus 2) decrease nEGFR function and 3) increase EGFR expression on the cell membrane.

Specific Aim 2: Determine if targeting nEGFR, via SFK or AKT inhibition, can increase therapeutic response of nEGFR positive, cetuximab-resistant NSCLC tumors to cetuximab.

Specific Aim 3: Determine the prevalence of nEGFR protein expression in NSCLC using IHC and AQUA/Vectra analyses and determine if it serves as a prognostic factor in NSCLC.

BODY:

In this first year of this DoD-LCRP award we have focused on two areas of the SOW; the first area being focused on Specific Aim 1 and the second on Specific Aim 3. We have also highlighted additional findings below with a thorough description.

Specific Aim 1: To determine if SFK or AKT inhibition can 1) block EGFR translocation to the nucleus and if this leads to decreased nEGFR function and 2) increase EGFR expression on the cell membrane.
In the first year we focused our energies to determine if in vivo, treatment with dasatinib could decrease nuclear levels and increase membrane levels. We performed an experiment using HC1, HC4 and HC8 (high nEGFR) (HC4 depicted) cetuximab-resistant clone to determine if our in vitro findings of targeting nEGFR would translate in vivo. To accomplish this we inoculated the dorsal flank of athymic nude mice with cetuximab-resistant clone HC4. Mice were treated with vehicle or 70mg/kg/day of dasatinib for three days. Tumors were harvested, fixed and prepared for VECTRA imaging (Quantitative per-cell measurement of nuclear, cytoplasmic, and membranous protein expression for EGFR distribution (Figure 1)). The results of this experiment indicated dasatinib treatment significantly reduced nEGFR levels, while increasing membrane/cytoplasmic EGFR levels in vivo. This data provides proof-of-principle that targeting nEGFR with dasatinib leads to decreased nEGFR with subsequent increased membrane EGFR (Figure 1). We are now performing this work with AKT blockade to determine which form leads to better redistribution of the EGFR and decreases nEGFR in vivo.

Specific Aim 3: Determine the prevalence of nEGFR protein expression in NSCLC using IHC and AQUA analyses and determine if it serves as a prognostic factor in NSCLC.

The focus of this aim was to use two NSCLC TMAs with various stages of NSCLC. In a first effort we focused our time on the 88 patient TMA that contained only stage I and II patients. Briefly, the findings are summarized below:

**Introduction:** Nuclear EGFR (nEGFR) has been identified in various human tumor tissues, including cancers of the breast, ovary, oropharynx, and esophagus, and has predicted poor patient outcomes. We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC).

**Methods:** Resected stages I and II NSCLC specimens were evaluated for nEGFR protein expression using immunohistochemistry (IHC). Cases with at least one replicate core containing ≥5% of tumor cells demonstrating strong dot-like nucleolar EGFR expression were scored as nEGFR positive.

**Results:** Twenty-three (26.1% of the population) of 88 resected specimens stained positively for nEGFR. Nuclear EGFR protein expression was associated with higher disease stage (45.5% of stage II vs. 14.5% of stage I; p = 0.023), histology (41.7% in squamous cell carcinoma vs. 17.1% in adenocarcinoma; p = 0.028), shorter progression-free survival (PFS) (median PFS 8.7 months [95% CI 5.1–10.7 mo] for nEGFR positive vs. 14.5 months [95% CI 9.5–17.4 mo] for nEGFR negative; hazard ratio (HR) of 1.89 [95% CI 1.15–3.10]; p = 0.011), and shorter overall survival (OS) (median OS 14.1 months [95% CI 10.3–22.7 mo] for nEGFR positive vs. 23.4 months [95% CI 20.1–29.4 mo] for nEGFR negative; HR of 1.83 [95% CI 1.12–2.99]; p = 0.014).

**Conclusions:** Expression of nEGFR protein was associated with higher stage and squamous cell histology, and predicted shorter PFS and OS, in this patient cohort. Nuclear EGFR serves as a useful independent prognostic variable and as a potential therapeutic target in NSCLC.

This paper was published in the journal of Lung Cancer is attached. We are now currently focusing on the larger TMA with stages I-IV.

**Novel findings stemming directly from this line of investigation:**

During this first year efforts we took a novel approach in our laboratory to identify the key regions of the C-terminal that impart EGFRs nuclear transcriptional function. We have provided a description of this work below.

**Development and characterization of nEGFR transcriptional null mutant isogenic lines; Tools to understand nEGFR in tumor biology and cetuximab resistance.**
To date, two functions of nEGFR have been identified: 1) the ability to phosphorylate substrates within the nucleus (kinase-dependent activity) and 2) the ability to serve as a co-transcription factor (kinase-independent activity, Figure 2)\textsuperscript{19}. To first demonstrate that nEGFR transcriptional activity is kinase-independent we expressed wildtype EGFR (EGFRWT) in CHO cells along with the Cyclin D1-Luciferase reporter gene (D1-Luc), a promoter that EGFR regulates\textsuperscript{7}, in the absence or presence of gefitinib (Figure 2B). The results of these experiments indicated that EGFRWT could induce D1-Luc expression and gefitinib failed to block this induction. Further, a kinase-dead EGFR (EGFRKD) control was also able to induce transcription of the D1-Luc reporter, thus strengthening the case that EGFR transcription is kinase-independent.

To determine if nEGFRs transcriptional activities are crucial for tumor biology and resistance to cetuximab we developed an EGFR mutant null for its transcriptional activity (Figure 3)\textsuperscript{18}. To create a transcriptional EGFR mutant, we mapped the C-terminal domains necessary for transcriptional potential as we had done previously for HER3\textsuperscript{17,18}. This approach identified two regions, which were termed B\textsubscript{1} and B\textsubscript{2}, for bipartite 1 and bipartite 2, in the C-terminal of the EGFR tail that are necessary to confer transcription potential, (Figure 3). Deletion of these regions (EGFRΔB\textsubscript{1}ΔB\textsubscript{2}) abrogated transcriptional potential of known nEGFR target genes (Figure 3&4)\textsuperscript{18}.

This nEGFR transcriptional mutant, and several controls, were used to create an isogenic cell system in the LSCC NCI-H226 cell parental cell line (Figure 4). This line was chosen for several reasons: 1) it is the SCC line where we developed and investigated cetuximab resistance in LSCC, 2) H226 has been used by several groups to study metastatic spread using mouse model systems\textsuperscript{23} and 3) this line gives up to 75% metastatic lung lesions when used in flank xenograft systems\textsuperscript{21}. To create an isogenic model system we used the H226 parental line and stably knocked down EGFR expression using a 3'UTR shEGFR vector (A kind gift from Jeff Settleman\textsuperscript{22}). This line was then used to add back nEGFR mutant variants to create an isogenic system that includes: 1) Parental H226, 2) 3'UTR shEGFR, 3) EGFRWT, 4) EGFRΔB\textsubscript{1}ΔB\textsubscript{2} and 5) EGFR-NLS2 (nuclear deficient EGFR 23) (Figure 4A). Controls: We will make use a known fully activated, nuclear deficient EGFR mutant, EGFR-NSL\textsubscript{2}\textsuperscript{23,24}, where the EGFR NLS was mutated from a “RRRHIVKRTLRR” to a RRRHIVAAATLRR rendering it deficient for nuclear entry. In addition, in order to study predominantly nuclear signaling all constructs were fused to the triplicate SV40-NLS sequence to increase the nuclear levels of EGFR, a technique previously used in our lab\textsuperscript{5}. Characterization of this model membrane signaling as indicated by activation of MAPK and AKT (Figure 4A) Further, EGFRWT and EGFRΔB\textsubscript{1}ΔB\textsubscript{2} are nuclear localized, whereas EGFR-NLS2 was deficient (Figure 4B). In addition, both the EGFRWT and EGFRΔB\textsubscript{1}ΔB\textsubscript{2} phosphorylate known nuclear substrates of the EGFR PCNA\textsuperscript{25} and DAPK\textsuperscript{26}, respectively, whereas the EGFR-NLS2 was unable to enter the nucleus and phosphorylate known EGFR substrates (DAPK and PCNA) (Figure 4C). Next we tested if the EGFRΔB\textsubscript{1}ΔB\textsubscript{2} was transcriptionally null for known EGFR target genes including Cyclin D1, iNOS, COX2 and B-Myb. The results of this experiment, using
qPCR, indicated that transfection of EGFRWT was able to increase transcription of nEGFR target genes whereas EGFRΔB1ΔB2 and EGFRNLS were not (Figure 4D). Finally, it was determined that the EGFRΔB1ΔB2 impaired proliferative potential (Figure 4E). Collectively, this isogenic system will enable us to better define the role of nEGFR in NSCLC.

**KEY RESEARCH ACCOMPLISHMENTS:**

- We have demonstrated that tumors that harbor high levels of nEGFR can targeted by dasatinib, which leads to the increased levels on the membrane. (Aim 1 SOW)
- We have determined that nEGFR is a prognostic factor in stage I and II NSCLC. (Aim 3 SOW)
- We have developed a novel EGFR mutant that is kinase functional, but transcriptionally null. We did this through a series of mapping experiments. This will allow us to directly test the role of nEGFR transcriptional function in biology and cetuximab resistance.

**REPORTABLE OUTCOMES:**

- manuscripts, abstracts, presentations;

- licenses applied for and/or issued N/A
- degrees obtained that are supported by this award; N/A/
- development of cell lines, tissue or serum repositories; N/A
- infomatics such as databases and animal models, etc.; N/A
- funding applied for based on work supported by this award;
  With the funding from this DoD award we developed a novel EGFR mutant that is null for its transcriptional functions. This has allowed us to ask new and novel questions centered on the role of nEGFR transcription and its role in NSCLC tumor biology (angiogenesis, metastasis, transformation, etc) and cetuximab resistance. This approach and questions was recently submitted to the DoD-LCRP entitled “Bifurcation of nuclear EGFR function to elucidate its role in tumor biology and cetuximab resistance of the lung” and was invited for a full application. We are extremely excited about this opportunity to continue our efforts to understand the role of nEGFR in lung cancer.
- employment or research opportunities applied for and/or received based on experience/training supported by this award N/A

**CONCLUSION:**

NSCLC is a deadly disease that is driven by a multitude of factors. One of these factors is the epidermal growth factor receptor (EGFR). One of the most prominent molecular targeting agents to the EGFR is the antibody cetuximab. However, most patients develop resistance to this antibody. We have found in models of cetuximab
resistance that the EGFR changes its location, to the nucleus, where it is not accessible to the large antibody. Our work over the last several years has discovered how to target the nEGFR, by blocking its translocation to the nucleus through Src Family Kinase blockade.

In this first year we have determined that nEGFR can serve as a prognostic factor in early stage NSCLC patients. We are building on this finding to see if nEGFR can serve as a prognostic factor for late stage patients, a goal of Aim 3. Secondly we have determined that we can target nEGFR in vivo and redistribute to the membrane in vivo, a critical first step for re-sensitizing to cetuximab. Finally, we have developed a new avenue by developing a novel EGFR mutant that lacks its transcriptional potential. This will allow us to directly test the role of nEGFR in biology and cetuximab resistance.

We have made no medical products during the first year of this experimentation.

REFERENCES:


**APPENDICES:** Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, study questionnaires, and surveys, etc.

Early report

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer

Anne M. Traynor a, Tracey L. Weigel b, Kurt R. Oettel c, David T. Yang d, Chong Zhang e, KyungMann Kim e, Ravi Salgia f, Mari lida g, Toni M. Brand g, Tien Hoang a, Toby C. Campbell a, Hilary R. Herna a, Deric L. Wheeler g,a

a Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
b Department of Surgery and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
c Gundersen Lutheran Center for Cancer & Blood Disorders, Gundersen Lutheran Medical Center, LaCrosse, WI, USA
d Department of Pathology and Laboratory Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
e Department of Biostatistics and Medical Informatics and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
f Department of Medicine and Cancer Research Center, Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
g Department of Human Oncology and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

A R T I C L E   I N F O

Article history:
Received 8 January 2013
Received in revised form 15 February 2013
Accepted 28 March 2013

Keywords:
Non-small cell lung cancer
Nuclear
Epidermal growth factor receptor
Prognosis
Biomarker
Survival analysis

A B S T R A C T

Introduction: Nuclear EGFR (nEGFR) has been identified in various human tumor tissues, including cancers of the breast, ovary, oropharynx, and esophagus, and has predicted poor patient outcomes. We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC).

Methods: Resected stages I and II NSCLC specimens were evaluated for nEGFR protein expression using immunohistochemistry (IHC). Cases with at least one replicate core containing ≥5% of tumor cells demonstrating strong dot-like nuclear EGFR expression were scored as nEGFR positive.

Results: Twenty-three (26.1% of the population) of 88 resected specimens stained positively for nEGFR. Nuclear EGFR protein expression was associated with higher disease stage (45.5% of stage II vs. 14.5% of stage I; p = 0.023), histology (41.7% in squamous cell carcinoma vs. 17.1% in adenocarcinoma; p = 0.028), shorter progression-free survival (PFS) (median PFS 8.7 months [95% CI 5.1–10.7 mo] for nEGFR positive vs. 14.5 months [95% CI 9.5–17.4 mo] for nEGFR negative; hazard ratio (HR) of 1.89 [95% CI 1.15–3.10]; p = 0.011), and shorter overall survival (OS) (median OS 14.1 months [95% CI 10.3–22.7 mo] for nEGFR positive vs. 23.4 months [95% CI 20.1–29.4 mo] for nEGFR negative; HR of 1.83 [95% CI 1.12–2.99]; p = 0.014).

Conclusions: Expression of nEGFR protein was associated with higher stage and squamous cell histology, and predicted shorter PFS and OS, in this patient cohort. Nuclear EGFR serves as a useful independent prognostic variable and as a potential therapeutic target in NSCLC.

© 2013 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Non-small cell lung cancer is a heterogeneous malignancy, comprised of multiple histologic subtypes. Predicting the course of disease based upon staging is suboptimal. The identification of biological markers of aggressive clinical behavior is needed in an effort to individualize treatment and develop novel therapeutic targets.

Protein expression of membrane bound EGFR was neither prognostic nor predictive of efficacy with the use of erlotinib, gefitinib, or cetuximab in NSCLC [1,2]. However, emerging preclinical and clinical evidence supports the role of nEGFR in enhancing tumor cell growth, survival, and resistance to systemic and radiation therapies [3–10]. Herein, we report identification of nEGFR protein expression as an independent prognostic variable in early stage NSCLC.

2. Materials and methods

2.1. Patients and specimen collection

For this retrospective analysis of patients who underwent curative intent resections, de-identified tumor specimens from 88 deceased patients with stages I and II NSCLC were collected from the University of Wisconsin Hospitals and Clinics (UWHC; Madison, WI) and from the Gundersen Lutheran Medical Center (GLMC; Wisconsin, WI).
LaCrosse, WI). Patients did not receive either pre- or post-operative anti-cancer therapy. We also collected: age, sex, histology, smoking history, pathologic stage (AJCC Staging 6th edition), type of resection, date of relapse, and date of death. Approval for this research was obtained from the IRBs of UW-Madison and the GLMC.

2.2. Tissue microarray construction and protein expression analyses

Tumor tissue quality and pathology were confirmed by the study pathologist (D.TY). Tissues were harvested within 30 min of resection, fixed with 10% neutral buffered formalin and embedded in paraffin. Areas of tumor and adjacent benign tissue were marked on a representative H & E stained section. Duplicate 0.6 mm cores from the corresponding paraffin block were punched out and assembled with a Manual Tissue Arrayer (Beecher Instruments, Sun Prairie, WI).

For nEGFR protein expression analyses, tissue sections were deparaffinized and antigen retrieval was performed in citrate buffer (pH 6.0) with 0.05% Tween-20. Samples were incubated with EGFR polyclonal antibody (sc-03, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4C. Samples were washed and incubated in secondary antibody for 1 hour followed by incubation with Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA, USA). 3,3-Diaminobenzidine staining was used as the color-developing reagent. Slides were counterstained with Mayer hematoxylin, dehydrated through a graded series of ethanol washes to xylene, and coverslipped with Permount (Fisher, Springfield, NJ).

We initially hypothesized that assessment of nEGFR protein would require the quantitative and subcellular localization capacity of automated quantitative analysis (AQUA). When we observed that the nuclear staining of EGFR protein revealed a distinct, robust nucleolar pattern (Fig. 1A) that clearly contrasted with negative cases (Fig. 1B) using routine IHC staining, we switched to the IHC methodology due to its easier translation to clinical practice. The nEGFR staining pattern was scored by the study pathologist at 5% increments by visual estimation at 20× magnification. Accordingly, cases with at least one replicate core containing at least 5% of tumor cells demonstrating strong dot-like nucleolar EGFR IHC protein expression were scored as nEGFR positive.

2.3. Statistical analyses

Our endpoints were protein expression of nEGFR and PFS and OS. Originally this study had an approximate power of 0.902, 0.747 and 0.477 to detect a hazard ratio of 2, 1.75 and 1.5, respectively, using a two-sided log-rank test at a significance level 0.05, given the sample size of 88 when the AQUA score was dichotomized using its median. The prognostic impact of nEGFR was assessed using the log-rank test and Cox proportional hazards regression models for PFS and OS. Kaplan–Meier method was used to summarize PFS and OS for patients per nEGFR IHC. Association between nEGFR protein expression and sex, histology, smoking history and pathologic stage was assessed using Fisher’s exact test.

3. Results

3.1. Patient characteristics

Table 1 summarizes the characteristics of the 88 patient samples studied. None of the patients received either pre- or post-operative anti-cancer therapy. The median PFS and OS for our population

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>88</td>
</tr>
<tr>
<td>Median age (range)</td>
<td>73 (43–96 yrs)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>55 (62.5%)</td>
</tr>
<tr>
<td>Female</td>
<td>33 (37.5%)</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>41 (46.6%)</td>
</tr>
<tr>
<td>Squamous cell</td>
<td>36 (40.9%)</td>
</tr>
<tr>
<td>Bronchioloalveolar</td>
<td>4 (4.5%)</td>
</tr>
<tr>
<td>Large cell</td>
<td>3 (3.4%)</td>
</tr>
<tr>
<td>Non-small cell, NOS</td>
<td>2 (2.3%)</td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td>2 (2.3%)</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
</tr>
<tr>
<td>Current or former</td>
<td>84 (95.5%)</td>
</tr>
<tr>
<td>Type of surgery</td>
<td></td>
</tr>
<tr>
<td>Lobectomy</td>
<td>80 (90.9%)</td>
</tr>
<tr>
<td>Pneumonectomy</td>
<td>7 (8%)</td>
</tr>
<tr>
<td>Bilobectomy</td>
<td>1 (1.1%)</td>
</tr>
<tr>
<td>Disease stage</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>23 (26.1%)</td>
</tr>
<tr>
<td>IB</td>
<td>32 (36.4%)</td>
</tr>
<tr>
<td>IIA</td>
<td>9 (10.2%)</td>
</tr>
<tr>
<td>IIB</td>
<td>24 (27.3%)</td>
</tr>
<tr>
<td>T stage</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>31 (35.2%)</td>
</tr>
<tr>
<td>T2</td>
<td>52 (59.1%)</td>
</tr>
<tr>
<td>T3</td>
<td>5 (5.7%)</td>
</tr>
<tr>
<td>N stage</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>60 (68.2%)</td>
</tr>
<tr>
<td>N1</td>
<td>28 (31.8%)</td>
</tr>
<tr>
<td>Nuclear EGFR protein expression</td>
<td>Positive</td>
</tr>
</tbody>
</table>
were 11.3 months (95% CI 9.1–16.2 mo) and 22.0 months (95% CI 15.9–24.7 mo), respectively, shorter than expected. Fifty-nine patients experienced disease relapse. Since only four patients were non-smokers, and seven underwent a pneumonectomy, these two clinical characteristics were dropped from further analyses.

Twenty-three (26.1% of the population) of 88 patients had specimens that stained positively for nEGFR (Fig. 1A). When nEGFR expression was seen, greater than 40% of tumor cells were positive in most cases. Nuclear EGFR was seen in between 1% and 4% of tumor cells very rarely (4/165 tumor cores). Control cores comprised of EGFR positive ductal carcinoma of the breast and matched adjacent normal lung from each tumor were represented on the TMA as external and internal controls, respectively. Cytoplasmic and membrane EGFR staining were confirmed in the breast control, and no nEGFR expression was observed in any of the adjacent normal lung tissue. Table 2 depicts the distribution of nEGFR positivity per IHC staining across our tumor samples.

3.2. Nuclear EGFR protein expression and survival

According to the log-rank test, nEGFR protein positivity was associated with shorter PFS (median PFS 8.7 months [95% CI 5.1–10.7 mo] for nEGFR positive vs. 14.5 months [95% CI 9.5–17.4 mo] for nEGFR negative; HR = 1.89 [95% CI 1.15–3.10]; p = 0.011), and shorter OS (median OS 14.1 months [95% CI 10.3–22.7 mo] for nEGFR positive vs. 23.4 months [95% CI 20.1–29.4 mo] for nEGFR negative; HR = 1.83 [95% CI 1.12–2.99]; p = 0.014).

3.3. Nuclear EGFR protein expression and prognosis

According to Fisher’s exact test, nEGFR protein positivity was associated with squamous cell histology, compared to adenocarcinoma (nEGFR positive in 41.7% of patients’ samples with squamous cell vs. 17.1% in adenocarcinoma specimens, p = 0.028), and with higher disease stage (nEGFR positive in 45.5% of stage II vs. 14.5% of stage I, p = 0.023). Nuclear EGFR protein expression was not associated with patient’s sex, or T or N status.

According to Cox proportional hazard models, of the baseline clinical characteristics (sex, disease stage, histology, T, N, and age), only age was at least marginally associated with PFS (p = 0.073), but was not associated with OS. Also nEGFR protein positivity in patients’ specimens was associated with shorter PFS, after controlling for age, with an HR of 1.68 (95% CI 1.01–2.81, p = 0.046), and with shorter OS with an HR of 1.83 (95% CI 1.12–2.99, p = 0.016).

4. Discussion

Nuclear EGFR was first observed in hepatocytes during liver regeneration. Translocation from the cell membrane to the nucleus has been reported with numerous receptor tyrosine kinases (RTKs), including all HER family receptors, MET, and VEGFR2 [3,4]. Protein expression of nEGFR has correlated with shortened survival in cancers of the breast, ovary, and oropharyngeal and esophageal squamous cells. Approximately 25–50% of the tumor cells expressed nEGFR [5–8].

Nuclear translocation of full length EGFR can be initiated by ligand binding, irradiation, cetuximab, and cisplatin [4,9,10]. Early events for movement of EGFR from the plasma membrane to the nucleus include phosphorylation of the dimerized receptor by SRC family kinases and AKT [10,11]. These stimuli induce internalization to endocytic vesicles, EGFR then undergoes retrograde translocation through the Golgi apparatus to the endoplasmic reticulum, whereupon it moves from the outer nuclear membrane to the inner nuclear membrane via interaction between importin β and the nuclear pore complex. In the inner nuclear membrane, EGFR can interact with Sec61 for removal from the membrane and release into the nucleus [4,12].

Within the nucleus three functions have been identified for the EGFR. First, EGFR associates with STAT3, STAT5 and E2F1 to act as a transcriptional co-activator, independent of its kinase activity, to increase the expression of target genes that worsen
the malignant phenotype (cyclin D1, iNOS, B-myb, c-Myc, Aurora kinase A, Breast Cancer Resistance Protein, and COX-2) [3,4,13]. Second, nEGFR phosphorylates proliferating cell nuclear antigen, promoting DNA replication [14]. Third, it activates DNA-dependent protein kinase within the nucleus, stimulating DNA repair following exposure to irradiation and cisplatin [15]. This study demonstrates that a distinct nucleolar pattern of EGFR protein was associated with significantly shorter PFS and OS, higher stage and squamous histology in patients with early stage NSCLC. These correlations were not confounded by exposure to additional anti-cancer therapies. A limitation of our study is our shorter than expected overall survival; this is most certainly related to the fact that all samples were selected from patients who had expired by the time of our analyses. Within our patient cohort, however, nEGFR protein expression was detected in just over a quarter of our samples and was statistically associated with higher stage and squamous histology. These results are consistent with findings from other disease sites [5–8].

Our group, and others, have shown in experimental models that nEGFR contributes to treatment resistance with cetuximab, gefitinib, erlotinib, and irradiation [10,11,15]. For example, we demonstrated that NSCLC cells that developed acquired resistance to cetuximab expressed increased levels of nEGFR, and that forced expression of nEGFR rendered cetuximab-sensitive cells resistant to cetuximab, both in vitro and in vivo [3,10]. Similarly, Liccardi et al. showed that cells expressing EGFR with mutations that impair nuclear transport demonstrated reduced repair of DNA strand breaks following ionizing radiation and reduced repair of interstrand cross-links following exposure to cisplatin, as compared to cells capable of directing EGFR to the nucleus [15]. Conversely, sensitivity in cetuximab-resistant NSCLC cells was re-established after blocking nuclear translocation of EGFR by co-exposing cells to either dasatinib, a SRC family kinase inhibitor, or MK2206, an AKT inhibitor [10,11].

Investigating the functions of nuclear RTKs in untreated cancer cells also serves as a focus of research [16]. Using sequential immunoprecipitation and immunoelectron microscopy assays, Li and colleagues demonstrated that ErbB2 co-localizes with β-actin and RNA polymerase-I (RNA Pol I) to the nucleoli in multiple breast cancer cell lines. Activation of this complex enhanced binding of RNA Pol I to rDNA, expediting rRNA synthesis and protein translation. These authors proposed that localization of ErbB2 to the nucleus and nucleoli contributed to tumorigenesis by increasing rRNA synthesis and protein translation. Nuclear EGFR has been identified in multiple tumor types in patients who did not undergo prior EGFR inhibiting therapy [5–8], as was the case with our population. Biological mechanisms that signal localization of EGFR to the nucleolus in untreated patients, as well as the potential role of such localization in tumor development, are under study in our laboratory.

5. Conclusion

We have identified nEGFR as a predictor of shortened survival in patients with early stage NSCLC. Preclinical data highlights the kinase dependent and independent processes by which nEGFR stimulates tumor cell growth, progression, and survival [3,4,10,11]. This raises the question of whether or not nEGFR represents not only a useful prognostic factor in NSCLC, but also a potential therapeutic target. The biological functions of nEGFR, and strategies to improve the efficacy of cetuximab, cisplatin and radiation by disrupting nuclear translocation of EGFR, remain the subjects of our translational research efforts.

Conflict of interest

No author of this article had any financial or personal relationships with other people or organizations that could inappropriately influence or bias this article.

Acknowledgements

This work was supported in part by the University of Wisconsin Carbone Cancer Center 2P30 CA014520-34, the University of Wisconsin Foundation Creating Hope Campaign for Lung Cancer Research, the Gundersen Lutheran Medical Foundation, the Clinical and Translational Science Award program, previously through the National Center for Research Resources grant 1UL1RR025011, and now through the National Center for Advancing Translational Sciences grant 9UL1TR000021, grant RSG-10-193-01-TBG from the American Cancer Society (DLW), and by NIH grant T32 GM08.1061-01A2 from the Graduate Training in Cellular and Molecular Pathogenesis of Human Diseases (TMB). This manuscript was written solely by the authors; the funding sources for this project did not assist in the writing or reviewing of this submission and did not pay the authors for the conduct or writing of this work. The funding sources exerted no role in the design of this project, nor in the data collection, analyses, or interpretation.

References